Arbovirus Testing Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Arbovirus Testing Market size was estimated at USD 1.21 Billion in 2025 and is projected to grow at a 5.8% CAGR from 2026 to 2035, exceeding USD 2.13 Billion by 2035. The industry revenue for 2026 is calculated at USD 1.27 billion.

• Base Year Value (2025): USD 1.21 Billion
• CAGR (2026-2035): 5.8%
• Forecast Year Value (2035): USD 2.13 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Arbovirus Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 44.10% share in 2025, supported by established diagnostic laboratory networks, advanced healthcare infrastructure, and routine infectious disease surveillance using molecular and serological testing.
  • Asia Pacific is projected to grow at a 6.55% CAGR as expanding public health surveillance, recurring mosquito-borne disease outbreaks, and greater demand for early diagnosis increase testing adoption.

• Segment Momentum:

  • ELISA-based tests lead with a 51.62% share due to scalable, cost-effective screening and established use in routine diagnostics, enabling efficient processing of large sample volumes in clinical laboratories.
  • RT-PCR tests are the fastest-growing segment as demand increases for precise molecular detection, offering higher diagnostic confidence and improved ability to identify arboviral infections early.

• Market Expansion Drivers:

  • Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance.
  • Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening.
  • WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives.

• Leading Market Participants:

  Leading players in the arbovirus testing market include Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Merck KGaA (Germany), Agilent Technologies, Inc. (United States), bioMérieux SA (France).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.21 Billion
  • Projected Market Size: USD 2.13 Billion by 2035
  • Growth Forecasts: 5.8% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: ELISA-based Tests (Type) | Diagnostic Laboratories (End Use)
  • Emerging Opportunity Segment: RT-PCR Based Tests (Type) | Research Centers (End Use)

Market Growth Drivers and Industry Trends

Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance

As dengue and Zika cases become more frequent and geographically widespread, healthcare systems are under pressure to distinguish arboviral infections quickly from other febrile illnesses, especially during seasonal surges and localized outbreaks. This is driving demand for the arbovirus testing market by increasing procurement of rapid diagnostic kits, PCR assays, and surveillance-oriented testing workflows that can support early case identification and public health response. Hospitals, public laboratories, and vector-control authorities rely on faster diagnostic turnaround to guide triage, confirm outbreak clusters, and trigger containment measures, which in practice raises testing volumes and supports broader adoption of decentralized and high-throughput arbovirus testing platforms.

Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening

Routine screening needs in hospitals and diagnostic laboratories are supporting market expansion for the arbovirus testing market through wider use of ELISA-based assays, which fit established laboratory workflows and allow cost-effective processing of larger sample volumes. Their practical appeal comes from compatibility with existing equipment, technician familiarity, and the ability to standardize serology testing for suspected dengue, Zika, and related infections without requiring highly specialized molecular infrastructure for every case. As a result, laboratories increasingly incorporate ELISA into frontline screening algorithms, reserving more complex confirmatory methods for selected samples and reinforcing steady reagent and kit consumption.

WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives

International health programs are driving market development in the arbovirus testing market by improving laboratory capacity, procurement systems, and testing protocols in regions where arboviral disease burden is highest. When WHO-led and donor-backed initiatives support reference lab networks, workforce training, assay validation, and harmonized diagnostic guidelines, they reduce variability in testing practices and make adoption decisions easier for ministries of health and public health laboratories. This creates more consistent demand for approved assays and supporting instruments, while standardization efforts help integrate arbovirus diagnostics into broader neglected tropical disease and outbreak preparedness frameworks.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of arbovirus infections	1.80%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Adoption of advanced diagnostic testing	2.00%	Medium term (2–5 yrs)	North America, Asia Pacific	Low	Moderate
Expansion of healthcare and lab infrastructure in emerging markets	2.00%	Long term (5+ yrs)	Asia Pacific, Latin America	Low	Slow
Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance	2.10%	High	Asia Pacific, Latin America	High	Near Term
Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening	1.90%	Moderate	North America	High	Near Term
WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives	1.70%	High	Africa, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading position in the arbovirus testing market in 2025, accounting for a 44.10% share. This leadership is supported by established diagnostic laboratory networks, broad access to molecular and serological testing, and routine integration of infectious disease surveillance into public health practice. The region’s market activity is reinforced by faster test deployment through well-developed healthcare infrastructure and consistent use of confirmatory testing in hospital, reference lab, and government settings where vector-borne disease monitoring is closely managed.

Asia Pacific is projected to expand at a 6.55% CAGR over the forecast period in the arbovirus testing market, driven by rising testing demand in areas exposed to recurring mosquito-borne disease outbreaks and expanding public health detection efforts. Growth is being fueled by the practical need for earlier diagnosis, wider surveillance coverage, and improved access to testing across densely populated and climatically vulnerable locations. As healthcare systems increase their focus on outbreak identification and response, adoption is accelerating across laboratories and care settings that require timely detection to manage disease spread.

Key Country Insights

United States

Public Health Surveillance

The U.S. arbovirus testing market is shaped by increasing surveillance efforts and the need for rapid diagnostics during seasonal outbreaks. Laboratories and healthcare providers in the U.S. are expanding molecular testing capabilities to improve detection and epidemiological monitoring.

Japan

Vector Monitoring Initiatives

Japan places emphasis on surveillance and diagnostic readiness for mosquito-borne diseases, particularly in densely populated regions. Healthcare institutions are increasingly adopting sensitive testing methods that facilitate early detection and outbreak management.

South Korea

Rapid Response Diagnostics

South Korea is enhancing arbovirus testing infrastructure to support faster identification of vector-borne infections and strengthen public health response systems. The market is seeing growing adoption of molecular assays and integrated disease surveillance programs.

Germany

Diagnostic Preparedness Programs

Germany is strengthening arbovirus testing capabilities through improved laboratory preparedness and vector-borne disease monitoring initiatives. The market prioritizes accurate diagnostic tools that support timely identification of imported and locally transmitted infections.

France

Integrated Disease Detection

France maintains active interest in arbovirus diagnostics due to ongoing monitoring of mosquito-borne disease risks in metropolitan and overseas territories. Diagnostic providers are focusing on testing solutions that enable efficient surveillance and outbreak containment strategies.

Italy

Seasonal Surveillance Capacity

Italy is expanding arbovirus testing capabilities to support seasonal monitoring and early identification of vector-borne infections. Public health authorities and laboratories are increasingly adopting advanced diagnostic technologies to improve response coordination and disease tracking.

Segment Leadership and Growth Trends

  Type Segment Analysis: ELISA-based Tests (Largest Segment) vs RT-PCR Based Tests (Fastest-Growing Segment)

ELISA-based Tests held a 51.62% share of the arbovirus testing market in 2025, reflecting their entrenched role in routine diagnostic workflows where laboratories need practical, scalable, and cost-conscious testing methods. Their leadership is underpinned by broad familiarity across clinical settings, established use in high-volume screening, and the operational ease of integrating these assays into standard laboratory processes. In the arbovirus testing market, this makes ELISA-based Tests a dependable choice where turnaround efficiency and testing throughput matter more than adopting newer molecular formats for every case.

RT-PCR Based Tests are the fastest-growing segment in the arbovirus testing market because demand is rising for methods that can support more precise and earlier-stage detection in settings where diagnostic certainty is increasingly important. Growth is being reinforced by the need to distinguish arboviral infections with greater analytical confidence, especially as testing requirements become more sensitive to timely identification and clinical decision-making. Compared with conventional serology-led approaches, RT-PCR Based Tests are gaining momentum where laboratories and healthcare systems are placing higher value on molecular confirmation and refined detection capability.

End Use Segment Analysis: Diagnostic Laboratories (Largest Segment) vs Research Centers (Fastest-Growing Segment)

Diagnostic Laboratories accounted for the largest share of the arbovirus testing market in 2025, supported by their central role in handling routine patient testing and processing large sample volumes within established healthcare networks. Their leadership comes from day-to-day diagnostic demand, existing laboratory infrastructure, and their position as the primary point of test execution for suspected arboviral infections. In the arbovirus testing market, these practical service-delivery dynamics keep Diagnostic Laboratories at the forefront of end-use demand.

Research Centers represent the fastest-growing end-use segment in the arbovirus testing market as expanding scientific focus on arboviral surveillance, detection methods, and disease characterization continues to increase testing activity in research environments. Their momentum is tied to the need for deeper investigative work around pathogen behavior and assay performance, which creates stronger demand for advanced and exploratory testing use than in routine diagnostic settings. Relative to established clinical end users, Research Centers are growing faster because their testing demand is being shaped by active study programs and evolving research priorities rather than stable everyday diagnostic volumes.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	ELISA-based Tests, RT-PCR Based Tests, Others	ELISA-based Tests	RT-PCR Based Tests
End Use	Diagnostic Laboratories, Hospitals, Research Centers, Others	Diagnostic Laboratories	Research Centers

Competitive Landscape and Market Positioning

Key companies in the arbovirus testing market:

1. Abbott Laboratories (United States)

2. Thermo Fisher Scientific Inc. (United States)

3. F. Hoffmann-La Roche Ltd (Switzerland)

4. Siemens Healthineers AG (Germany)

5. QIAGEN N.V. (Netherlands)

6. Bio-Rad Laboratories Inc. (United States)

7. EUROIMMUN Medizinische Labordiagnostika AG (Germany)

8. Merck KGaA (Germany)

9. Agilent Technologies Inc. (United States)

10. bioMérieux SA (France)

The arbovirus testing market is advancing through improved diagnostic accuracy and faster detection technologies. Enhanced testing platforms are enabling quicker outbreak identification and response. New diagnostic solution launches are improving laboratory efficiency and reliability. Collaborative research initiatives are further strengthening detection capabilities, supporting the arbovirus testing market in addressing evolving infectious disease challenges.

Industry Development/News

Company Name	Date	Key Development
Astellas Pharma Inc.	May-23	Astellas Pharma Inc. committed to supporting Phase III of the Global Health Innovative Technology Fund (GHIT Fund), collaborating with cross-sector funding partners to advance global health innovation. The initiative indirectly supports development pathways for infectious disease diagnostics, reinforcing broader ecosystem funding for arbovirus-related testing and surveillance innovation.
Anitoa Systems	May-22	Anitoa Systems introduced a portable RT-PCR molecular diagnostic platform for dengue detection using the Maverick qPCR instrument and lyophilized multiplex RT-PCR reagents. The solution enables rapid identification of dengue infections and expands portable molecular testing capabilities, strengthening point-of-care arbovirus diagnostic accessibility.
Mylab	Jul-22	Mylab launched the PathoDetect Extended Monsoon Fever Panel, a multiplex RT-PCR assay designed to detect multiple arboviruses and related infections including dengue, zika, and malaria. The compact test system delivers results within approximately two hours and supports scaled diagnostic capacity for outbreak surveillance and infectious disease management.
FDA	Jan-25	The U.S. FDA issued streamlined regulatory guidance for emerging pathogen in vitro diagnostic approvals, reducing barriers for arbovirus testing solutions. The policy is expected to accelerate commercialization timelines for new diagnostic technologies and expand market entry opportunities for RT-PCR and other molecular test platforms.
FDA	Nov-23	The FDA approved IXCHIQ, the first chikungunya vaccine in the United States, influencing arbovirus testing demand by increasing pre- and post-vaccination diagnostic requirements. The approval contributes to evolving clinical workflows for arbovirus surveillance and reinforces demand for confirmatory and differential diagnostic testing solutions.